Category: analysis
-
Rare but Real: Understanding Secondary Cancers After CAR T-Cell Therapy and What It Means for Future Treatments
Secondary cancers, particularly T-cell lymphomas, are an emerging concern following chimeric antigen receptor (CAR) T-cell therapy, especially due to potential viral vector integration causing oncogenesis. However, the risk and mechanisms of such secondary malignancies remain understudied. In this study, researchers reviewed the clinical experience with adoptive CAR T-cell therapy at Stanford since 2016, analyzing 724…